Compugen Ltd. Stock
Compugen Ltd. Stock
A loss of -2.860% shows a downward development for Compugen Ltd..
The community is currently still undecided about Compugen Ltd. with 1 Buy predictions and 0 Sell predictions.
With a target price of 3 € there is potential for a 119.3% increase which would mean more than doubling the current price of 1.37 € for Compugen Ltd..
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | -2.860% | 5.069% | -6.173% | -10.821% | -9.524% | 47.892% | - |
| Intellia Therapeutics Inc | -4.250% | -6.699% | -6.061% | -40.633% | -32.354% | -79.776% | -82.519% |
| Chromadex Corp | 0.910% | 0.000% | -9.756% | -7.500% | 7.767% | 273.989% | 20.130% |
| Polynovo Ltd | 1.490% | 3.030% | 0.741% | -45.161% | -43.802% | -45.600% | -70.690% |
Comments
Compugen Ltd. (NASDAQ: CGEN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) had its price target lowered by analysts at Truist Financial Co. from $5.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
